Opinion|Videos|July 16, 2024
Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL
John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Explore the logistics and best practices aimed at optimizing therapeutic response, minimizing potential adverse events, and maximizing off-treatment benefits.
- How do you initiate venetoclax therapy in your practice, including titration and management of potential AEs and risk of tumor lysis syndrome?
- What insights/implications do recent real-world data provide?
Advertisement
Related to this article
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
5